Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ralimetinib - Eli Lilly and Company

Next Previous
X
Search
Drug Profile

Ralimetinib - Eli Lilly and Company

Alternative Names: LSN-2322600; LY-2228820; LY2228820 dimesylate; p38 MAP inh; Ralimetinib mesylate

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Centre Jean Perrin; Eli Lilly and Company
  • Class 2 ring heterocyclic compounds; Antineoplastics; Fluorobenzenes; Imidazoles; Pyridines; Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ovarian cancer
  • Phase I/II Glioblastoma
  • No development reported Colorectal cancer; Lymphoma; Multiple myeloma; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 28 Oct 2019 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Germany (PO)
  • 28 Oct 2019 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
  • 28 Oct 2019 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Germany (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top